Axsome Therapeutics, Inc. (AXSM)
Chart Events
Performance Outlook
| Previous Close | 31.51 |
| Open | 32.01 |
| Bid | 32.89 x 1100 |
| Ask | 33.03 x 800 |
| Day's Range | 31.65 - 33.26 |
| 52 Week Range | 19.38 - 74.10 |
| Volume | |
| Avg. Volume | 1,071,817 |
| Market Cap | 1.284B |
| Beta (5Y Monthly) | 2.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.72 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 81.21 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AXSM
Related Research
- Axsome Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 05/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic MoatyesterdayArgus Research
- Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2022
With that as a backdrop, let's consider two biotech stocks that don't grab a lot of headlines but deserve serious consideration: Incyte (NASDAQ: INCY) and Axsome Therapeutics (NASDAQ: AXSM). Incyte is a drugmaker with a particular focus on the field of oncology. Its best-selling product is called Jakafi, which treats some types of bone marrow cancer, among other conditions.
- PR Newswire
Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the publication of the results from the pivotal ASCEND Phase 2 clinical trial of AXS-05 (dextromethorphan-bupropion) in major depressive disorder (MDD). AXS-05 is a novel, oral, investigational N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity. The article, "Effect of AXS-05 (Dextrometh
- Motley Fool
2 Biotech Stocks That Could Go Parabolic
Biotech stocks have taken a beating to start the year, with the S&P Biotech Industry Index down more than 49% so far. There are several reasons a biotech stock could go parabolic -- that is, have its shares see a sharp rise in a short period. The company could be the buyout target of a merger deal with a larger pharmaceutical company.
